Ferrara Napoleone 4

What Happened Director Napoleone Ferrara was granted a derivative award (an option) for 9,000 shares of Kalaris Therapeutics on June 3, 2026. The filing reports the transaction at $0.00 per share (total reported value $0) because this is a grant of a derivative instrument rather than an open‑market purchase or sale. This is a compensation grant to a director — a routine, non‑sale insider transaction rather than a market directional trade.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 4, 2026 (appears timely under Form 4 rules).
• Transaction type: Award/Grant (derivative option) — 9,000 shares reported at $0.00.
• Shares owned after transaction: Not reported in the provided excerpt.
• Footnote: The option vests in full on the earlier of (i) June 3, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service.
• No indication of immediate sale or cashless exercise in this filing.

Context This filing reports a director compensation grant (an option). Such awards are commonly used to compensate and retain board members and do not, by themselves, indicate buying or selling sentiment. Because it’s a derivative grant with vesting conditions, the economic interest becomes actionable only if/when the option vests and is exercised.